CJC-1295 & Ipamorelin:
Synergistic Growth Hormone Research
CJC-1295 and Ipamorelin are frequently co-researched as a complementary GHRH/GHRP pair. Together they activate the growth hormone axis through two distinct but synergistic mechanisms, making them a popular combination in preclinical GH secretion research.
What Are CJC-1295 & Ipamorelin?
CJC-1295 is a 30-amino acid synthetic analog of growth hormone-releasing hormone (GHRH). It binds GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and pulsatile release. The Drug Affinity Complex (DAC) modification in CJC-1295 w/DAC extends half-life by binding serum albumin, creating sustained GHRH receptor activation. CJC-1295 without DAC (Mod GRF 1-29) produces a shorter, more physiological pulse.
Ipamorelin is a selective fifth-generation growth hormone releasing peptide (GHRP). It acts at the ghrelin/GH secretagogue receptor (GHSR-1a) with high selectivity, stimulating GH release without significantly raising cortisol or prolactin — a key differentiator from earlier GHRPs. The two peptides operate on separate receptor pathways, creating additive-to-synergistic GH amplification when co-administered.
Why Combine Them?
CJC-1295 and Ipamorelin activate the GH axis through two independent receptor pathways — resulting in amplified GH pulse magnitude compared to either agent alone.
CJC-1295
Ipamorelin
Key Research Findings
Research on CJC-1295, Ipamorelin, and their combination covers pituitary biology, body composition, metabolic regulation, and bone metabolism.
GH Pulse Amplification
Combination studies show significantly greater peak GH secretion than either CJC-1295 or Ipamorelin alone. The GHRH + GHRP combination exploits the natural two-signal requirement for maximum somatotroph GH exocytosis.
IGF-1 Elevation
CJC-1295 studies demonstrate dose-dependent increases in serum IGF-1 that persist for several days (w/DAC formulation). Sustained IGF-1 elevation is associated with downstream anabolic signaling in muscle and bone research models.
Body Composition Research
Rodent studies with GHRH/GHRP combinations show increased lean body mass, reduced adipose tissue accumulation, and improved nitrogen balance — mediated downstream via IGF-1 and direct GH actions.
Bone Density Models
GH secretagogue research in aged rodent models shows positive effects on bone mineral density and cortical bone thickness, mediated through IGF-1-stimulated osteoblast activity.
Sleep Architecture Research
GHRP studies, including Ipamorelin analogs, show GH secretion is linked to slow-wave sleep. Preclinical models suggest GH secretagogues may influence sleep quality metrics in rodent sleep studies.
Selective Safety Profile
A key research finding with Ipamorelin vs. earlier GHRPs (GHRP-6, GHRP-2): minimal stimulation of cortisol and prolactin in rodent models, suggesting receptor selectivity that may be advantageous in experimental design.
Proposed Mechanisms of Action
CJC-1295 binds GHRH receptors on pituitary somatotroph cells, activating Gs-protein-coupled adenylyl cyclase and raising intracellular cAMP. PKA activation increases GH gene transcription and triggers stored GH exocytosis.
Ipamorelin binds the ghrelin/GH secretagogue receptor (GHSR-1a), activating Gq/11 protein signaling, phospholipase C, and IP3-mediated calcium release from the ER. This calcium surge is the immediate trigger for GH vesicle exocytosis.
GHRPs including Ipamorelin suppress somatostatin (SST) release from the hypothalamus, reducing its inhibitory tone on the pituitary — further amplifying net GH output when combined with CJC-1295.
GH released by pituitary somatotrophs travels to the liver, stimulating hepatic IGF-1 synthesis. IGF-1 then mediates many downstream anabolic effects in muscle, bone, and adipose tissue through IGF-1R/PI3K/Akt signaling.
CJC-1295 w/DAC incorporates a maleimido-propionic acid group that covalently binds Cys34 of serum albumin. This reversible conjugation creates a depot effect, extending half-life from ~30 min to 6–8 days and maintaining elevated GHRH receptor stimulation.
Active Research Applications
GH Axis Research
Dose-response and pharmacokinetic studies measuring GH and IGF-1 serum levels in rodent models following CJC-1295 and Ipamorelin administration.
Body Composition Studies
Lean mass and fat mass analysis in aged rodent models using DEXA scanning or tissue weighing following GHRH/GHRP combination protocols.
Bone Metabolism
Bone mineral density studies, osteoblast culture assays, and bone histomorphometry in GH secretagogue-treated animal models.
Neurological Research
Ghrelin receptor studies in the CNS, hypothalamic GH axis regulation research, and sleep-GH secretion relationship models.
Metabolic Rate Studies
Resting metabolic rate and indirect calorimetry studies in rodent models examining GH-mediated lipolysis and energy substrate partitioning.
Pituitary Biology
Primary pituitary cell culture studies and ex vivo pituitary gland assays characterizing CJC-1295 and Ipamorelin receptor binding and GH secretion kinetics.
Protocol Notes for Researchers
CJC-1295 & Ipamorelin — Research Grade ≥99%
Research-grade purity ≥99% · Third-party HPLC verified · Ships from the U.S.
All products sold by Lumen Peppers are intended exclusively for in vitro laboratory research and investigative purposes. These compounds are not approved by the FDA for human or veterinary use. They are not drugs, supplements, or medications. Lumen Peppers makes no therapeutic claims. Researchers are solely responsible for ensuring compliance with all applicable laws and regulations in their jurisdiction.